Artificial intelligence for aging and longevity research: Recent advances and perspectives

Alex Zhavoronkov, Polina Mamoshina, Quentin Vanhaelen*, Morten Scheibye-Knudsen, Alexey Moskalev, Alex Aliper

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftReviewForskningpeer review

119 Citationer (Scopus)
908 Downloads (Pure)

Abstract

The applications of modern artificial intelligence (AI) algorithms within the field of aging research offer tremendous opportunities. Aging is an almost universal unifying feature possessed by all living organisms, tissues, and cells. Modern deep learning techniques used to develop age predictors offer new possibilities for formerly incompatible dynamic and static data types. AI biomarkers of aging enable a holistic view of biological processes and allow for novel methods for building causal models—extracting the most important features and identifying biological targets and mechanisms. Recent developments in generative adversarial networks (GANs) and reinforcement learning (RL) permit the generation of diverse synthetic molecular and patient data, identification of novel biological targets, and generation of novel molecular compounds with desired properties and geroprotectors. These novel techniques can be combined into a unified, seamless end-to-end biomarker development, target identification, drug discovery and real world evidence pipeline that may help accelerate and improve pharmaceutical research and development practices. Modern AI is therefore expected to contribute to the credibility and prominence of longevity biotechnology in the healthcare and pharmaceutical industry, and to the convergence of countless areas of research.

OriginalsprogEngelsk
TidsskriftAgeing Research Reviews
Vol/bind49
Sider (fra-til)49-66
Antal sider18
ISSN1568-1637
DOI
StatusUdgivet - 2019

Citationsformater